Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

3.040 -0.180 (-5.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immuneering Corporation - Class A Common Stock

< Previous 1 2 3 4 5 6 Next >
Expert Ratings for Immuneering
 
Via Benzinga
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Jefferies Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Analyst Doubles Immuneering Price Target Citing Initial Data Validation
 
Via Benzinga
What 7 Analyst Ratings Have To Say About Immuneering
 
Via Benzinga
Why Shares of Immuneering Jumped This Week
Immuneering is ready to share information regarding its lead therapy. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023
 
Via Benzinga
Immuneering Announces $30 Million Underwritten Offering
From Immuneering Corporation
Via GlobeNewswire
Looking Into Immuneering's Return On Capital Employed
 
Via Benzinga
Immuneering Earnings Preview
 
Via Benzinga
Immuneering's Return On Capital Employed Insights
 
Via Benzinga
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
- Investor call to be held at 9:00 a.m. ET on April 18, 2023 - 
From Immuneering Corporation
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
 
Via Benzinga
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise 
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
From Immuneering Corporation
Via GlobeNewswire
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces Participation in March Investor Conferences
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Management to host conference call on Monday, March 6 at 4:30 p.m. ET 
From Immuneering Corporation
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
 
Via Benzinga
Immuneering To Present at Guggenheim 2023 Oncology Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
From Immuneering Corporation
Via GlobeNewswire
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC
From Immuneering Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.